We are live on ! Find out more
Omega Fund Management

Omega Fund Management Portfolio holdings

AUM $186M Turnover 18.18%
1-Year Est. Return 155.23%
This Fund
S&P 500
This Quarter Est. Return
+31.5%
1 Year Est. Return
+155.23%
3 Year Est. Return
+106.31%
5 Year Est. Return
+162.6%
10 Year Est. Return
+764.79%
AUM
$186M
AUM Growth
+$22.5M
Cap. Flow
-$14.6M
Cap. Flow %
-7.85%
Top 10 Hldgs %
100%
Holding
11
New
1
Increased
–
Reduced
1
Closed
1
Avg Time Held
2.5 years
Top 10 Avg Time Held
1.9 years
Top 20 Avg Time Held
2.5 years

Top Buys

Rank Stock Value
1
ODTX icon
Odyssey Therapeutics
ODTX
+$50.7K

Top Sells

Rank Stock Value
1
BCAX icon
Bicara Therapeutics
BCAX
+$12.7M
2
REPL icon
Replimune Group
REPL
+$1.91M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
BCAX icon
1
Bicara Therapeutics
BCAX
$1.12B
$54.1M 29.14%
1,822,150
-570,000
-24% -$12.7M
2024 Q3
7 quarters
NUVB icon
2
Nuvation Bio
NUVB
$1.58B
$45.9M 24.72%
8,081,089
– –
2021 Q1
21 quarters
KMTS icon
3
Kestra Medical Technologies
KMTS
$1.75B
$26M 14%
1,022,149
– –
2025 Q1
5 quarters
BBOT icon
4
BridgeBio Oncology
BBOT
$212M
$25.1M 13.5%
3,289,661
– –
2025 Q3
3 quarters
BBNX icon
5
Beta Bionics
BBNX
$1.11B
$20.6M 11.11%
1,316,183
– –
2025 Q1
5 quarters
ALMS icon
6
Alumis Inc
ALMS
$843M
$6.79M 3.66%
241,255
– –
2024 Q2
8 quarters
SANA icon
7
Sana Biotechnology
SANA
$706M
$2.94M 1.59%
843,750
– –
2021 Q1
21 quarters
IMA icon
8
ImageneBio Inc
IMA
$46M
$2.69M 1.45%
455,361
– –
2021 Q1
21 quarters
ENGN icon
9
enGene Therapeutics
ENGN
$106M
$1.52M 0.82%
876,357
– –
2023 Q4
10 quarters
ODTX icon
10
Odyssey Therapeutics
ODTX
$928M
$54.1K 0.03%
+2,893
New +$50.7K
2026 Q2
0 quarters
REPL icon
11
Replimune Group
REPL
$1.17B
– –
-248,672
Closed -$1.91M –

Similar funds

Leigh Baldwin & Co
Leigh Baldwin & Co Cazenovia, New York $186M AUM 40.09% 1-Year Est. Return
Godshalk Welsh Capital Management
Godshalk Welsh Capital Management Radnor, Pennsylvania $186M AUM 18.63% 1-Year Est. Return
Fingerlakes Wealth Management
Fingerlakes Wealth Management Ithaca, New York $186M AUM 30.5% 1-Year Est. Return
Tranquilli Financial Advisor
Tranquilli Financial Advisor Clinton, New Jersey $186M AUM 18.12% 1-Year Est. Return
Melfa Wealth Management
Melfa Wealth Management Westborough, Massachusetts $185M AUM 17.73% 1-Year Est. Return
SMP
Santa Monica Partners Palm Beach Gardens, Florida $185M AUM 35.82% 1-Year Est. Return
Palliser Capital (UK)
Palliser Capital (UK) London, United Kingdom $186M AUM 45.72% 1-Year Est. Return
MBWA
Marin Bay Wealth Advisors San Anselmo, California $186M AUM

Omega Fund Management's Q2 2026 Portfolio in Review

As of Q2 2026, Omega Fund Management held 11 positions worth $186M, up 14% from $163M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Omega Fund Management withdrew a net $14.6M in Q2 2026, closing 1 position and reducing 1 holding. Its most notable exit was Replimune Group, an estimated $1.91M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Omega Fund Management opened a new position in Odyssey Therapeutics worth $54.1K.

  • Omega Fund Management's largest Q2 2026 buy was Odyssey Therapeutics: 2,893 shares worth $54.1K.
  • Omega Fund Management's biggest Q2 2026 reduction was Bicara Therapeutics, cutting an estimated $12.7M.
  • Omega Fund Management fully exited Replimune Group in Q2 2026, selling an estimated $1.91M.
  • Omega Fund Management's ten largest holdings make up 100% of its $186M portfolio in Q2 2026.
  • Omega Fund Management opened 1 new position and closed 1 in Q2 2026.
  • Omega Fund Management's portfolio value rose 14% quarter-over-quarter to $186M.

Based on Omega Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.